A Schulze-Bonhage

University of Freiburg, Freiburg, Baden-Württemberg, Germany

Are you A Schulze-Bonhage?

Claim your profile

Publications (177)378.69 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Various brain stimulation techniques are in use to treat epilepsy. These methods usually require surgical implantation procedures. Transcutaneous vagus nerve stimulation (tVNS) is a non-invasive technique to stimulate the left auricular branch of the vagus nerve at the ear conch.
    No preview · Article · Jan 2016 · Brain Stimulation
  • Source
    B J He · G Nolte · K Nagata · D Takano · T Yamazaki · Y Fujimaki · T Maeda · Y Satoh · S Heckers · M S George · [...] · R Hashimoto · K Watanabe · Y Kawasaki · K Laimböck · L J Koorenhof · S J Swithenby · A Martins-Mourao · K W Song · J F Knebel · K Laimboeck ·

    Full-text · Dataset · Jan 2016
  • Source
    M. Hirsch · V. A. Coenen · D. H. Heiland · N. Lützen · O. Staszewski · A. Schulze-Bonhage
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Among the tumors associated with chronic epilepsy, dysembryoplastic neuroepithelial tumor and ganglioglioma are the most common besides angiocentric glioma, pleomorphic xanthoastrocytoma and pilocytic astrocytoma. These tumors are usually considered as being benign. Objective To determine the best conservative and surgical treatment of tumors associated with epilepsy. Material and methods This article presents case reports of malignant transformation of a dysembryoplastic neuroepithelial tumor and of a tumor initially diagnosed as a ganglioglioma based on magnetic resonance imaging (MRI) criteria. Description of references in the literature on epilepsy surgery and the neuro-oncology of epilepsy-associated tumors. Results In the case of the initially histopathologically diagnosed dysembryoplastic neuroepithelial tumor, a malignant transformation occurred 5 years after incomplete resection. The differentiation from a glioblastoma was possible through the analysis of the methylation profile. In another case a tumor assumed to be a ganglioglioma showed an increase in size after 6 years. Initial histopathological results revealed a glioblastoma. The analysis of the methylation profile suggested the diagnosis of an anaplastic pleomorphic xanthoastrocytoma and as a differential diagnosis an anaplastic ganglioglioma. Tumor progress correlated with the worsening of seizures. Conclusion Recent studies have shown that in the treatment of predominantly benign epilepsy-associated tumors neuro-oncological aspects should also be taken into account in addition to the epileptological considerations. In the case of malignant transformation epigenetic screening (methylation profiles) can help to classify the tumor entity more precisely.
    Full-text · Article · Dec 2015 · Der Nervenarzt
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pathological changes in excitability of cortical tissue commonly underlie the initiation and spread of seizure activity in patients suffering from epilepsy. Accordingly, monitoring excitability and controlling its degree using antiepileptic drugs (AEDs) is of prime importance for clinical care and treatment. To date, adequate measures of excitability and action of AEDs have been difficult to identify. Recent insights into ongoing cortical activity have identified global levels of phase synchronization as measures that characterize normal levels of excitability and quantify any deviation therefrom. Here, we explore the usefulness of these intrinsic measures to quantify cortical excitability in humans. First, we observe a correlation of such markers with stimulation-evoked responses suggesting them to be viable excitability measures based on ongoing activity. Second, we report a significant covariation with the level of AED load and a wake-dependent modulation. Our results indicate that excitability in epileptic networks is effectively reduced by AEDs and suggest the proposed markers as useful candidates to quantify excitability in routine clinical conditions overcoming the limitations of electrical or magnetic stimulation. The wake-dependent time course of these metrics suggests a homeostatic role of sleep, to rebalance cortical excitability.
    Full-text · Article · Nov 2015 · Proceedings of the National Academy of Sciences
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: This study investigates the performance of a cardiac-based seizure detection algorithm (CBSDA) that automatically triggers VNS (NCT01325623). METHODS: Thirty-one patients with drug resistant epilepsy were evaluated in an epilepsy monitoring unit (EMU) to assess algorithm performance and near-term clinical benefit. Long-term efficacy and safety were evaluated with combined open and closed-loop VNS. RESULTS: Sixty-six seizures (n=16 patients) were available from the EMU for analysis. In 37 seizures (n=14 patients) a ≥20% heart rate increase was found and 11 (n=5 patients) were associated with ictal tachycardia (iTC, 55% or 35bpm heart rate increase, minimum of 100bpm). Multiple CBSDA settings achieved a sensitivity of ≥80%. False positives ranged from 0.5 to 7.2/h. 27/66 seizures were stimulated within ±2min of seizure onset. In 10/17 of these seizures, where triggered VNS overlapped with ongoing seizure activity, seizure activity stopped during stimulation. Physician-scored seizure severity (NHS3-scale) showed significant improvement for complex partial seizures (CPS) at EMU discharge and through 12 months (p
    Full-text · Article · Sep 2015 · Seizure
  • Source
    Andreas Schulze-Bonhage · Mandy Hintz
    [Show abstract] [Hide abstract]
    ABSTRACT: Perampanel (PER) is a novel antiepileptic drug recently introduced for the adjunctive treatment in epilepsy patients aged 12 years or older with partial-onset seizures with or without secondary generalization in the US and Europe. Its antiepileptic action is based on noncompetitive inhibition of postsynaptic AMPA receptors, decreasing excitatory synaptic transmission. Evaluation of efficacy in three placebo-controlled randomized Phase III studies showed that add-on therapy of PER decreased seizure frequencies significantly compared to placebo at daily doses between 4 mg/day and 12 mg/day. PER's long half-life of 105 hours allows for once-daily dosing that is favorable for patient compliance with intake. Long-term extension studies showed a 62.5%-69.6% adherence of patients after 1 year of treatment, comparing favorably with other second-generation antiepileptic drugs. Whereas these trials demonstrated an overall favorable tolerability profile of PER, nonspecific central nervous system adverse effects like somnolence, dizziness, headache, and fatigue may occur. In addition, neuropsychiatric disturbances ranging from irritability to suicidality were reported in several case reports; both placebo-controlled and prospective long-term extension trials showed a low incidence of such behavioral and psychiatric complaints. For early recognition of neuropsychiatric symptoms like depression, anxiety, and aggression, slow titration and close monitoring during drug introduction are mandatory. This allows on the one hand to recognize patients particularly susceptible to adverse effects of the drug, and on the other hand to render the drug's full potential of seizure control available for the vast majority of patient groups tolerating the drug well.
    Preview · Article · Aug 2015 · Patient Preference and Adherence
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epilepsy is both a disease of the brain and the mind. Here, we present the first of two papers with extended summaries of selected presentations of the Third International Congress on Epilepsy, Brain and Mind (April 3-5, 2014; Brno, Czech Republic). Epilepsy in history and the arts and its relationships with religion were discussed, as were overviews of epilepsy and relevant aspects of social cognition, handedness, accelerated forgetting and autobiographical amnesia, and large-scale brain networks. Copyright © 2015. Published by Elsevier Inc.
    Full-text · Article · Aug 2015 · Epilepsy & Behavior
  • Andreas Schulze-Bonhage
    [Show abstract] [Hide abstract]
    ABSTRACT: Epilepsy is a chronic disease which affects 1% of the population worldwide. As treatment is required for many years or decades, the long-term efficacy and tolerability of antiepileptic drugs are particularly important. Zonisamide (ZNS) is a second-generation antiepileptic drug with a unique structure and multiple mechanisms of action. Here, recently published long-term outcomes of patient cohorts with focal epilepsy undergoing ZNS treatment are discussed. Whereas ZNS monotherapy maintains similar seizure control efficacy to carbamazepine after 2 years of treatment, seizure-free rates are low in pharmacoresistant patients undergoing late adjunctive therapy. In preselected patient populations derived from double-blind studies, long-term seizure reduction and responder rates support sustained ZNS efficacy, good adherence and long-term retention. Adverse effects include somnolence and weight decrease, but data suggest that long-term treatment with ZNS is safe with only rare newly occurring adverse effects, and good long-term tolerability also regarding mood, behavior, cognition and bone maturation.
    No preview · Article · Jul 2015 · Expert Review of Neurotherapeutics
  • Andreas Schulze-Bonhage
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Epilepsies are among the most common diseases of the CNS. As available antiepileptic drugs do not successfully control seizures in one-third of these patients, the development of drugs with new mechanisms of action is an urgent requirement. Areas covered: Preclinical and clinical data of the recently released antiepileptic drug perampanel are reviewed based on search in medical databases with special reference to its mechanism of action and to its pharmacokinetic properties relevant for clinical treatment. Pharmacodynamically, perampanel is a noncompetitive AMPA-receptor antagonist exerting its antiepileptic properties by modulating glutamatergic synaptic excitation. Pharmacokinetically, perampanel is characterized by a short Tmax but slow hepatic metabolism and a mean plasma half-life of 105 h, allowing for once-daily dosing. Perampanel has shown antiepileptic properties in several animal models of seizures and epilepsy, and in clinical studies significantly reducing partial-onset seizures in a dose range from 4 to 12 mg/day both in blinded short-term and in open-label long-term extension trials even in highly pharmacoresistant patients. Aside from adverse effects of dizziness and somnolence, neuropsychiatric disturbances have been reported in patient subgroups, making careful clinical monitoring during uptitration recommendable. Expert opinion: The use of perampanel focusing on control of abnormal synaptic excitation profits from favorable pharmacokinetics and from proven efficacy and overall good tolerability also in patient populations nonresponsive to treatment with previously available antiepileptic drugs.
    No preview · Article · Jun 2015 · Expert Opinion on Drug Metabolism & Toxicology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Technological advances are dramatically advancing translational research in Epilepsy. Neurophysiology, imaging, and metadata are now recorded digitally in most centers, enabling quantitative analysis. Basic and translational research opportunities to use these data are exploding, but academic and funding cultures prevent this potential from being realized. Research on epileptogenic networks, antiepileptic devices, and biomarkers could progress rapidly if collaborative efforts to digest this "big neuro data" could be organized. Higher temporal and spatial resolution data are driving the need for novel multidimensional visualization and analysis tools. Crowd-sourced science, the same that drives innovation in computer science, could easily be mobilized for these tasks, were it not for competition for funding, attribution, and lack of standard data formats and platforms. As these efforts mature, there is a great opportunity to advance Epilepsy research through data sharing and increase collaboration between the international research community.
    No preview · Article · Jun 2015 · Journal of clinical neurophysiology: official publication of the American Electroencephalographic Society
  • K.H. Somerlik-Fuchs · U.G. Hofmann · T. Stieglitz · A. Schulze-Bonhage

    No preview · Article · Mar 2015 · Brain Stimulation
  • K. Gau · N. Foit · C. Kaller · J. Zentner · I. Mader · A. Schulze-Bonhage · K. Wagner

    No preview · Conference Paper · Feb 2015

  • No preview · Conference Paper · Feb 2015
  • Victoria San Antonio-Arce · Andreas Schulze-Bonhage

    No preview · Article · Dec 2014 · Journal of Neurology Neurosurgery & Psychiatry
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BrainLinks-BrainTools aims to develop smart devices to inter-face with the brain. Among these, closed-loop stimulation devices promise new chances for patients suffering from pharmacoresistant epilepsy, assuming that effective stimula-tion parameters can be found. As the mechanisms of electrical brain stimulations are complex and poorly understood, animal experiments are needed to obtain insight into optimal parame-ter settings. Besides these, the loop can only be closed by reli-able seizure detection and prediction algorithms with high performance and at the same time low computational complex-ity. We present our results in this respect, based on the widely accepted kainate model, thought to resemble human temporal lobe epilepsy. More than 400 seizures could be recorded in more than 2500 h of synchronized video-EEG-acquisition. Video-and EEG-based detection algorithms were pro-grammed and seizure prediction methods tested. Those with the best performance in regard to reliability, celerity and pow-er consumption will be used in a closed-loop setup. This is a first step to evaluate closed-loop stimulation approaches and therewith widening possibilities for future clinical applications.
    Full-text · Conference Paper · Oct 2014
  • Source
    Johanna Derix · Olga Iljina · Johanna Weiske · Andreas Schulze-Bonhage · Ad Aertsen · Tonio Ball
    [Show abstract] [Hide abstract]
    ABSTRACT: Exchange of thoughts by means of expressive speech is fundamental to human communication. However, the neuronal basis of real-life communication in general, and of verbal exchange of ideas in particular, has rarely been studied until now. Here, our aim was to establish an approach for exploring the neuronal processes related to cognitive “idea” units (IUs) in conditions of non-experimental speech production. We investigated whether such units corresponding to single, coherent chunks of speech with syntactically-defined borders, are useful to unravel the neuronal mechanisms underlying real-world human cognition. To this aim, we employed simultaneous electrocorticography (ECoG) and video recordings obtained in pre-neurosurgical diagnostics of epilepsy patients. We transcribed non-experimental, daily hospital conversations, identified IUs in transcriptions of the patients’ speech, classified the obtained IUs according to a previously-proposed taxonomy focusing on memory content, and investigated the underlying neuronal activity. In each of our three subjects, we were able to collect a large number of IUs which could be assigned to different functional IU subclasses with a high inter-rater agreement. IU-related responses of brain activity showed significant modulations of the spectral magnitude in high gamma frequencies (70-150 Hz) in mouth motor, language, and higher-order association areas. Neuronal responses specific to different IU subclasses were observed in the inferior parietal and prefrontal cortex. Thus, IU-based analysis of ECoG recordings during non-experimental communication elicited topographically- and functionally-specific effects. We conclude that segmentation of spontaneous real-world speech in linguistically-motivated units is a promising strategy for elucidating the neuronal basis of mental processing during non-experimental communication.
    Full-text · Article · Jun 2014 · Frontiers in Human Neuroscience
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent evidence suggests that some seizures are preceded by preictal changes that start from minutes to hours before an ictal event. Nevertheless an adequate statistical evaluation in a large database of continuous multiday recordings is still missing. Here, we investigated the existence of preictal changes in long-term intracranial recordings from 53 patients with intractable partial epilepsy (in total 531 days and 558 clinical seizures). We describe a measure of brain excitability based on the slow modulation of high-frequency gamma activities (40-140 Hz) in ensembles of intracranial contacts. In prospective tests, we found that this index identified preictal changes at levels above chance in 13.2% of the patients (7/53), suggesting that results may be significant for the whole group (p < 0.05). These results provide a demonstration that preictal states can be detected prospectively from EEG data. They advance understanding of the network dynamics leading to seizure and may help develop novel seizure prediction algorithms.
    Full-text · Article · Apr 2014 · Scientific Reports
  • Source
    B Metternich · F Buschmann · K Wagner · A Schulze-Bonhage · L Kriston
    [Show abstract] [Hide abstract]
    ABSTRACT: Testing of verbal fluency is currently part of standard presurgical neuropsychological assessment for patients with focal epilepsy. However, to date no systematic review has been conducted on semantic (SVF) and phonemic verbal fluency (PVF) in this patient group. The present review compares verbal fluency between healthy control subjects and subgroups of adult presurgical patients with focal epilepsy according to lateralisation and localisation of the dysfunction. PubMed was searched with a comprehensive search string. Abstracts of all studies and full-texts of potentially relevant studies were screened. Study quality was assessed by independent raters according to predefined criteria. 39 studies were included. Meta-analyses were performed to compare SVF and PVF across groups of patients with temporal (TLE) and frontal lobe epilepsy (FLE) as well as healthy controls (HC). Both patients with left- and right sided TLE were impaired on SVF and PVF compared to HC. Patients with left-sided TLE were slightly more impaired than patients with right-sided TLE. Patients with FLE showed a larger impairment in PVF than patients with TLE, whereas on SVF there was no difference between FLE and TLE. For TLE comparisons the study pool seems to have been sufficient, whereas more studies are needed to verify results for FLE. Semantic verbal fluency might not differentiate between FLE and TLE. While verbal fluency impairment was anticipated, especially in left-sided TLE and FLE patients, the impairment in patients with right-sided TLE was larger than expected. Results are discussed with regard to neuropsychological theory and practice.
    Full-text · Article · Mar 2014 · Neuropsychology Review
  • Andreas Schulze-Bonhage

    No preview · Article · Mar 2014 · Seizure
  • G. Leonhardt · A. Schulze-Bonhage
    [Show abstract] [Hide abstract]
    ABSTRACT: Die elektrische Stimulation der Hirnnerven V und X ist ein bislang palliatives Therapieverfahren für Epilepsiepatienten, die durch Medikamente nicht anfallsfrei werden, sich nicht für eine Operation eignen oder diese ablehnen. Sie bewirkt durch Aktivierung von Hirnstammkernen und des aufsteigenden Aktivierungssystem im Hirnstamm (,,ascending reticular activating system“, ARAS) eine Desynchronisierung kortikaler Aktivität. Ihre antikonvulsive Wirkung ist im Tierversuch gut belegt. Drei kleinere nichtrandomisierte Studien an Patienten mit pharmakorefraktären Epilepsien und eine Studie an Patienten mit pharmakorefraktären Depressionen belegten eine gute Wirksamkeit. Die bisher einzige randomisierte Phase-II-Studie bei Epilepsien, in der das Verfahren gegen eine aktive Kontrolle getestet wurde, zeigte erst zum letzten Untersuchungszeitpunkt (nach 18 Wochen) eine statistische Überlegenheit der Verumgruppe bei einem initial hohen Placeboeffekt der aktiven Kontrolle. Eine Phase-III-Studie ist in Planung. Eigene Erfahrungen mit dieser Methode lassen auf eine gute Verträglichkeit und Akzeptanz schließen. Ein positiver Einfluss auf die Stimmung wird von den meisten Patienten berichtet. Für die Bewertung der antikonvulsiven Wirkung sind die Anwendungen noch zu kurz und Patientenzahlen zu klein.
    No preview · Article · Feb 2014 · Zeitschrift für Epileptologie

Publication Stats

2k Citations
378.69 Total Impact Points


  • 2002-2016
    • University of Freiburg
      • Institute of Psychology
      Freiburg, Baden-Württemberg, Germany
  • 2008-2015
    • Universitätsklinikum Freiburg
      • Epilepsy Centre
      Freiburg an der Elbe, Lower Saxony, Germany
    • Bernstein Center for Computational Neuroscience Berlin
      Berlín, Berlin, Germany
  • 2000-2012
    • University of Bonn
      • Department of Neurobiology
      Bonn, North Rhine-Westphalia, Germany